Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rema Raman

Showing results (121-130 of 200) with videos related to

Pageof 20
Sort By:
Cerebrovascular Diseases (Basel, Switzerland)|November 29, 2008
Can comprehensive stroke centers erase the 'weekend effect'?Karen C Albright, Rema Raman, Karin Ernstrom, et al.
The New England Journal of Medicine|January 24, 2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's diseaseRachelle S Doody, Ronald G Thomas, Martin Farlow, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 25, 2022
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)Miriam T Ashford, Rema Raman, Garrett Miller, et al.
Age and Ageing|January 22, 2026
Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 studyAndrew L H Huynh, Shunran Wang, Kathryn Lee, et al.
JAMA Neurology|June 23, 2020
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical TrialSuzanne Craft, Rema Raman, Tiffany W Chow, et al.
The New England Journal of Medicine|July 26, 2013
A phase 3 trial of semagacestat for treatment of Alzheimer's diseaseRachelle S Doody, Rema Raman, Martin Farlow, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 14, 2022
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populationsMonica Rivera Mindt, Ozioma Okonkwo, Michael W Weiner, et al.
Psychological Trauma : Theory, Research, Practice and Policy|June 21, 2016
Randomized controlled trial of acceptance and commitment therapy for distress and impairment in OEF/OIF/OND veteransAriel J Lang, Paula P Schnurr, Sonia Jain, et al.
JAMA|November 4, 2010
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJoseph F Quinn, Rema Raman, Ronald G Thomas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 25, 2014
Estimating long-term multivariate progression from short-term dataMichael C Donohue, Hélène Jacqmin-Gadda, Mélanie Le Goff, et al.
Pageof 20

Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Cerebrovascular Diseases (Basel, Switzerland)|November 29, 2008
Can comprehensive stroke centers erase the 'weekend effect'?Karen C Albright, Rema Raman, Karin Ernstrom, et al.
The New England Journal of Medicine|January 24, 2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's diseaseRachelle S Doody, Ronald G Thomas, Martin Farlow, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 25, 2022
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)Miriam T Ashford, Rema Raman, Garrett Miller, et al.
Age and Ageing|January 22, 2026
Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 studyAndrew L H Huynh, Shunran Wang, Kathryn Lee, et al.
JAMA Neurology|June 23, 2020
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical TrialSuzanne Craft, Rema Raman, Tiffany W Chow, et al.
The New England Journal of Medicine|July 26, 2013
A phase 3 trial of semagacestat for treatment of Alzheimer's diseaseRachelle S Doody, Rema Raman, Martin Farlow, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 14, 2022
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populationsMonica Rivera Mindt, Ozioma Okonkwo, Michael W Weiner, et al.
Psychological Trauma : Theory, Research, Practice and Policy|June 21, 2016
Randomized controlled trial of acceptance and commitment therapy for distress and impairment in OEF/OIF/OND veteransAriel J Lang, Paula P Schnurr, Sonia Jain, et al.
JAMA|November 4, 2010
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trialJoseph F Quinn, Rema Raman, Ronald G Thomas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 25, 2014
Estimating long-term multivariate progression from short-term dataMichael C Donohue, Hélène Jacqmin-Gadda, Mélanie Le Goff, et al.
Pageof 20